Literature DB >> 35284515

Glucose-lowering agents and reduced risk of incident non-alcoholic fatty liver disease: new insights.

Alessandro Mantovani1, Rosa Lombardi2,3, Andrea Dalbeni4.   

Abstract

Entities:  

Year:  2022        PMID： 35284515      PMCID： PMC8847873          DOI： 10.21037/hbsn-2021-28

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  11 in total

Review 1.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 2.  Complications, morbidity and mortality of nonalcoholic fatty liver disease.

Authors:  Alessandro Mantovani; Eleonora Scorletti; Antonella Mosca; Anna Alisi; Christopher D Byrne; Giovanni Targher
Journal:  Metabolism       Date:  2020-01-30       Impact factor: 8.694

3.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  J Hepatol       Date:  2016-04-07       Impact factor: 25.083

Review 4.  Nonalcoholic Steatohepatitis: A Review.

Authors:  Adam C Sheka; Oyedele Adeyi; Julie Thompson; Bilal Hameed; Peter A Crawford; Sayeed Ikramuddin
Journal:  JAMA       Date:  2020-03-24       Impact factor: 56.272

5.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

Authors:  Philip N Newsome; Kristine Buchholtz; Kenneth Cusi; Martin Linder; Takeshi Okanoue; Vlad Ratziu; Arun J Sanyal; Anne-Sophie Sejling; Stephen A Harrison
Journal:  N Engl J Med       Date:  2020-11-13       Impact factor: 91.245

Review 6.  Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges.

Authors:  Jean-François Dufour; Cyrielle Caussy; Rohit Loomba
Journal:  Gut       Date:  2020-05-07       Impact factor: 23.059

Review 7.  Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials.

Authors:  Alessandro Mantovani; Graziana Petracca; Giorgia Beatrice; Alessandro Csermely; Amedeo Lonardo; Giovanni Targher
Journal:  Metabolites       Date:  2021-01-27

Review 8.  Treatments for NAFLD: State of Art.

Authors:  Alessandro Mantovani; Andrea Dalbeni
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

9.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

Authors:  Matthew James Armstrong; Piers Gaunt; Guruprasad P Aithal; Darren Barton; Diana Hull; Richard Parker; Jonathan M Hazlehurst; Kathy Guo; George Abouda; Mark A Aldersley; Deborah Stocken; Stephen C Gough; Jeremy W Tomlinson; Rachel M Brown; Stefan G Hübscher; Philip N Newsome
Journal:  Lancet       Date:  2015-11-20       Impact factor: 79.321

10.  Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.

Authors:  Judith van Dalem; Johanna H M Driessen; Andrea M Burden; Coen D A Stehouwer; Olaf H Klungel; Frank de Vries; Martijn C G J Brouwers
Journal:  Hepatology       Date:  2021-08-22       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.